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To investigate the role of gefitinib in patients with high-grade gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in
patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy. Adult patients with histologically
confirmed recurrent HGGs following surgery, radiotherapy and first-line chemotherapy, were considered eligible. Patients were
treated with gefitinib (250mgday
 1) continuously until disease progression. The primary end point was progression-free survival at 6
months progression-free survival at 6 months (PFS-6). Tissue biomarkers (epidermal growth factor receptor (EGFR) gene status and
expression, phosphorylated Akt (p-Akt) expression) were assessed. Twenty-eight patients (median age, 55 years; median ECOG
performance status, 1) were enrolled; all were evaluable for drug activity and safety. Sixteen patients had glioblastoma, three patients
had anaplastic oligodendrogliomas and nine patients had anaplastic astrocytoma. Five patients (17.9%, 95% CI 6.1–36.9%) showed
disease stabilisation. The overall median time to progression was 8.4 (range 2–104þ) weeks and PFS-6 was 14.3% (95% CI 4.0–
32.7%). The median overall survival was 24.6 weeks (range 4–104þ). No grade 3–4 gefitinib-related toxicity was found. Gefitinib
showed limited activity in patients affected by HGGs. Epidermal growth factor receptor expression or gene status, and p-Akt
expression do not seem to predict activity of this drug.
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Despite recent progress in the treatment of high-grade gliomas
(HGG), survival rates remain dismal. Genetic signatures of
chemoresistance, such as epidermal growth factor receptor (EGFR)
amplification and overexpression and activation of phosphatidyl-
inositol 3-kinase (PI3K)/Akt pathway, are present in a consistent
proportion of patients with HGG (Kleihues and WK, 2000).
At time of recurrence after surgery and radiotherapy, with or
without adjuvant chemotherapy, only a few options are available:
repeat surgery, re-irradiation in selected cases and/or chemotherapy.
However, responses with the currently available chemotherapy are
unsatisfactory. At the time of second recurrence after first-line
chemotherapy, hardly any of the options available are worth
pursuing. Even in anaplastic oligodendroglial tumours, that are
historically considered chemosensitive tumours, second-line treat-
ments seem to be scarcely effective (Triebels et al, 2004).
In this setting, novel agents such as new chemotherapy
compounds and anticancer agents against specific molecular
targets, have therefore been investigated. The protein, EGFR, one
of the most widely studied treatment targets, is a tyrosine kinase
receptor of the erbB family that is commonly implicated in several
different human tumour types. After ligand binding (EGF, TFG-
alpha, amphiregulin) EGFR undergo activation and, by recruiting
adaptor or signalling proteins, cause proliferative and antiapopto-
tic stimuli to spread into the cell. Epidermal growth factor
receptor-activated pathways include the mitogen-activated protein
kinase and the Akt cascades important for cell proliferation and
survival, respectively.
Small molecule tyrosine kinase inhibitors (TKIs), such as
gefitinib and erlotinib, interact with the intracellular domain
of EGFR by interfering with the intermolecular phosphorylations
of key tyrosine kinases in the activation loop of catalytic
TK domains, subsequently blocking the EGFR signalling pathways
(Mendelsohn and Baselga, 2003). Epidermal growth factor receptor
is an intriguing target in HGG because it is usually overexpressed
and the EGFR gene is amplified in most cases (Kleihues and
WK, 2000).
Gefitinib (IRESSA) acts as an ATPmimetic, binding the
intracytoplasmic ATP pocket domain and blocking receptor
phosphorylations and EGFR-mediated downstream pathways.
Preclinical studies have shown the potential activity of gefitinib
in intracranial tumours (Heimberger et al, 2002). Recently, in a
phase II trial on recurrent glioblastoma (GBM) by Rich et al
(2004b) gefitinib administration at a dose of 500mgday
 1 achieved
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sa stable disease rate of 42% and a median event-free survival of 8.1
weeks.
In the present multicentre phase II trial of the Gruppo Italiano
Cooperativo di Neuro-Oncologia (GICNO), the activity and safety
profile of oral gefitinib at the dose of 250mgday
 1 was evaluated in
patients with recurrent/progressive HGG, who had undergone
surgery, radiotherapy and chemotherapy.
An analysis was made of EGFR protein expression, gene status
and the PI3K/Akt pathway activation status by using the
phosphorylated Akt protein (p-Akt) expression.
PATIENTS AND METHODS
Treatment plan
Gefitinib was administered orally at a dose of 250mgday
 1 until
disease progression (PD) and/or significant clinical decline,
unacceptable toxicity or the patient decision to withdraw. Toxicity
was graded using the National Cancer Institute Common Toxicity
Criteria, version 2.0 (NCI-CTC v2.0).
For grade 2 skin rashes and diarrhoea not tolerated by the
patient, Gefitinib was suspended until the symptoms resolved. In
patients with other significant grade 2 nonhematologic toxicities,
treatment was withheld until the condition/symptoms resolved; in
those with grade 3 or 4 toxicity, treatment was discontinued, and
the patient was re-evaluated until toxicity was grade p1. Patients
with unresolved toxicity after 2 weeks were withdrawn from the
study.
Patient selection
Eligibility criteria included: age X18 years; life expectancy 48
weeks; histological diagnosis of progressive HGG (GBM, anaplastic
astrocytoma, anaplastic oligodendroglioma and anaplastic oligo-
astrocytoma) according to the WHO 2000 classification. Other
eligibility criteria were: ECOG performance status p2; stable
corticosteroid dose for at least 2 weeks before enrolment; normal
laboratory values for hepatic, renal and bone marrow function.
Patients on enzyme-inducing antiepileptic drugs (EIAEDs) were
considered eligible. Stable corticosteroids doses were mandatory
because of the effect on p450 cytochrome (Vecht et al, 2003), and
the compliance to response evaluation criteria in neuro–oncology
(Macdonald et al, 1990).
All the patients had undergone contrast computed tomography
or magnetic resonance imaging of the brain showing at least one
contrast-enhancing measurable lesion (X1cm), indicating PD or
recurrence after surgery, radiotherapy and no more than one line
of chemotherapy. None of the patients had undergone chemother-
apy in the 4 weeks before entering the study (6 weeks for patients
that received BCNU chemotherapy). All patients gave their fully
informed consent in writing to take part in the study, which was
approved by the Institutional Review Board (Bellaria Hospital,
Bologna, Italy), and was conducted according to the principles of
the Declaration of Helsinki and the rules of Good Clinical Practice.
Statistical analysis
In this multicentre, open-label, single-arm, phase II trial (1839IL/
0116) we evaluated the activity and toxicity profile of gefitinib
(IRESSA) 250mgday
 1 in HGG patients and any correlation with
molecular biomarkers. The primary endpoint was progression-free
survival at 6 months (PFS-6). This single-stage study of 28
assessable patients was designed to differentiate between a 6-
month PFS rate of 15 and 35% with a¼0.05 and b¼0.8.
Patients’ clinical and radiological evaluation was performed
every 8 weeks, or sooner if clinically indicated, according to
Macdonald’s criteria (Macdonald et al, 1990). Any variation in the
neurologic status and in the daily dosage of corticosteroids were
recorded.
The secondary end points were safety, time to progression
(TTP) and overall survival (OS). Tissue biomarkers (EGFR gene
status and expression, (p)Akt expression) were also evaluated.
Differences between and among groups were compared using
Fisher’s exact test or Pearson’s w
2 test for the following qualitative
variables: age (o60 or X60), gender (male vs female), histological
grade (WHO grade 3 vs 4 tumours), ECOG PS (0–1 vs 2), use of
EIAEDs (yes vs no), acneiform skin rash (presence vs absence),
diarrhoea (presence vs absence), EGFR and p-Akt protein
expressions (positive vs negative) and EGFR gene status (genetic
gain (amplifiedþpolysomic) vs diploid). Time to progression and
OS were calculated using the Kaplan–Meier method; different
groups were compared using the log-rank test. All statistical tests
were two sided, and statistical significance was defined as Po0.05.
All analyses were performed using the statistical package SPSS
version 11.0 (SPSS Italia Srl, Bologna, Italy).
Tissue preparation Tumour specimens, obtained before admin-
istration of cancer therapy were embedded in paraffin. Gene copy
number per cell was investigated by FISH using the LSI EGFR
SpectrumOrange/CEP7 SpectrumGreen probe (Vysis, Abbott
Laboratories, IL, USA), according to a published protocol (Hirsch
et al, 2003). Patients were classified according to the frequency
of tumour cells with specific numbers of copies of the EGFR gene
and chromosome 7 centromere: (1) disomy (two copies in 490%
of cells); (2) polysomy (X4 copies in X10% of cells); (3) gene
amplification (presence of a tight EGFR gene cluster and an EGFR
gene to chromosome ratio of X2 copies per cell in X10% of cells).
Epidermal growth factor receptor protein expression was
evaluated by immunohistochemistry (IHC) with the mouse
antihuman EGFR, clone 31G7 monoclonal antibody (Zymed
Laboratories, San Francisco, CA, USA) using methods and
assessment criteria described elsewhere (Hirsch et al, 2003).
Using the rabbit antimouse P-Akt (Ser 473) polyclonal antibody
(Cell Signaling Technology, Beverly, MA, USA), according to the
manufacturer’s instructions. Phosphorylated Akt and EGFR
expression were scored based on intensity and fraction of positive
cells as described elsewhere. (Cappuzzo et al, 2005). Tumour
samples were considered positive for p-Akt in patients with
nuclear staining intensity of at least 1þ in 410% of tumour cells.
The total score for EGFR protein expression was calculated by
multiplying the membrane staining intensity score and the fraction
score producing a total range of 0–400. For statistical analyses,
scores of 0–300 were considered negative/low expression, and
scores of 301–400 were considered positive/high expression.
Positive controls were chosen on non-small-cell lung cancer
specimens verified in previous studies from our group, in which
we found a statistical correlation between increased EGFR protein
expression and increased gene copy number.
All the negative controls were incubated with nonimmune
solution in place of primary antibody.
RESULTS
Twenty-eight Caucasian patients were enrolled between February
and December 2003. Their pretreatment characteristics, including
age, histology, performance status, surgery and dose of radio-
therapy, chemotherapy and antiepileptic treatments are sum-
marised in Table 1. All patients were evaluable for response.
DP and response
Progression-free survival at 6 months and PFS-12 were 14.3%.
(95%CI 4.0–32.7%) and 7.1% (95%CI 0.9–23.5%), respectively.
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sThe median TTP was 8.4 weeks (range 4–104þ). Progression-
free survival at 6 months and PFS-12 were both 12.5% (95%CI 1.6–
38.4%) in the GBM subgroup (Figure 1A and B).
The overall disease-control rate was 17.9% (95%CI 6.1–36.9%)
with 0 PR and 5s.d. (three GBM, one anaplastic astrocytoma and
one anaplastic oligodendroglioma), in the GBM subgroup was
12.5% (95%CI 1.6–38.4%) with 2s.d. Three of four patients with
disease control at 6 months were receiving EIAEDs. No differences
between patients that achieved s.d. against those progressing were
recorded by histology, age, corticosteroids and EIAEDs’ use.
Time to progression was significantly correlated with rash
(P¼0.05) (Figure 1B) but not with gender, histological tumour
grade, ECOG performance status, and use of EIAEDs and/or age.
OS
The median OS was 24.6 weeks (range 4–104þ), OS at 6 months
was 50% (95%CI 30.7–69.4%) and OS at 12 months, 14.3% (95%CI
4.0–32.7%).
Overall survival was statistically correlated with disease control
(P¼0.005) but not with gender, histological tumour grade, ECOG
performance status, use of EIAEDs, age and the molecular
biomarkers evaluated.
Toxicity
Grade 3/4 adverse events occurring during gefitinib treatment
were: grade 3 diarrhoea (n¼1) and neutropenia (n¼1), grade 4
acute pulmonary oedema (n¼1), pulmonary thromboembolism
(n¼1) and central nervous system haemorrhage (n¼1). The
investigators did not find any temporal and/or causal correlation
between the gefitinib treatment and these adverse events. Grade
1/2 gefitinib-related acneiform skin rash was common (32.1%).
Molecular biomarkers
The analysis of EGFR expression, p-Akt expression and EGFR
genetic status was performed on tissue samples from 21 patients;
results were available in 21, 21 and 19 cases, respectively (Figure 2).
Seven patients did not give informed consent for biomarkers
analysis. Epidermal growth factor receptor protein overexpression
was significantly correlated with EGFR genetic gain (P¼0.01) but
not with p-Akt expression. No correlations were found between
molecular biomarkers and PFS-6 (Table 2).
DISCUSSION
In a recent phase II trial, Rich et al (2004b) evaluated the role of
gefitinib at a dose of 500mgday
 1 in 57 patients with recurrent
GBM. None of the patients presented objective responses, and a
PFS-6 of 13.2% was achieved. Patients on EIAEDs received a
gefitinib dose escalation to 750–1000mgday
 1, and the authors
concluded that gefitinib was active in GBM patients. Epidermal
growth factor receptor protein expression and gene status and
EGFRvIII protein expression were not significantly correlated with
PFS-6 and OS.
In the present trial, the activity and toxicity profile of gefitinib at
a dose of 250mgday
 1 were evaluated in patients with HGG. This
dose was chosen following the experience of gefitinib use in lung
cancer treatment. In this setting, two large, randomised phase II
trials, investigated effectiveness and toxicity of gefitinib at 250mg
Table 1 Patients’ pretreatment characteristics
Characteristic (n¼28) n (%)
Gender
Male 17 (61)
Female 11 (39)
Age
Median 55
Range 29–70
ECOG performance status
0 3 (11)
1 21 (75)
2 4 (14)
Histology
GBM 16 (57)
Anaplastic oligodendroglioma 3 (11)
Anaplastic astrocytoma 9 (32)
Previous treatments
Surgery/biopsy 28 (100)
Radiotherapy 27 (96)
Chemotherapy 26 (93)
Antiepileptic drugs
None 4 (14)
EIAEDs 21 (75)
Non-EIAEDs 3 (11)
ECOG¼Eastern Cooperative Oncology Group; EIAEDs¼enzyme-inducing anti-
epileptic drugs; GBM¼glioblastoma.
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Figure 1 Kaplan–Meier curves for progression-free survival. (A) In overall population; (B) by rash.
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sor 500mgday
 1. No difference was found between response rates
and survivals following the two different dose schedules, whereas
the adverse event rates were higher in 500mgday
 1 arms (Fukuoka
et al, 2003; Kris et al, 2003). Moreover, data generated from phase I
studies of gefitinib showed that responses and disease stabiliza-
tions also occur at doses lower than 250mgday
 1 and gefitinib has
been shown to be effective at a dose of 50mgday
 1 in intermittent
schedules (Nakagawa et al, 2003). Also, PFS-6 does not appear to
be related to the dose escalation of a similar orally active TK
inhibitor, erlotinib in GBM patients on EIAEDs (Cloughesy et al,
2005).
We found an overall PFS-6 of 14.3%, and a PFS-6 of 12.5% in the
GBM subgroup. Disease control was achieved in five patients, and
three of the four patients with disease control at 6 months were on
EIAEDs.
However, the PFS-6 rate was too low to consider the drug active
in HGG.
Interestingly, the disease control obtained with gefitinib seemed
to provide HGG patients with a clinical benefit. A possible
explanation for these results may be that some glioma cells are
sensitive to gefitinib, even at low doses.
Molecular signatures of EGFR-TKI sensitivity have recently been
found in NSCLC: in particular, specific point mutations in the ATP
pocket domain correlate with dramatic responses to gefitinib
(Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004). Overall,
however, these mutations do not fully explain the whole spectrum
of gefitinib activity: responses and disease stabilisations have been
described in wild-type EGFR patients.
Furthermore, these mutations in the EGFR tyrosine kinase
domain have not been found in patients with glioma (Barber et al,
2004; Rich et al, 2004a; Marie et al, 2005). Rich et al (2004a)
showed that gefitinib-treated GBM patients with an event-free
survival of more than 24 weeks did not harbour such EGFR point
mutations . New indicators of EGFR TKIs sensitivity in patients
without EGFR point mutations are therefore required.
Findings in preclinical and clinical studies have highlighted the
activation status of the Akt protein (Cappuzzo et al, 2004; Sordella
et al, 2004).Akt, a serine/threonine kinase acts downstream of
EGFR to regulate many cellular processes, including cell survival,
proliferation and growth, and is activated by phosphorylation.
In the present study, we assessed EGFR protein expression, gene
amplification status and P-Akt protein expression, in tumours
without EGFR tyrosine kinase point mutations, such as HGG, in
order to understand why disease is controlled, sometimes for a
long-lasting period, by gefitinib in a fraction of patients.
However, we did not find any significant correlation between
disease control and molecular biomarkes.
Recently, other molecular biomarkers have been evaluate in the
analyses of two groups. Haas-Kogan et al (2005) showed that
response to erlotinib was associated with EGFR expression and
Figure 2 P-Akt IHC expression examples: (A) negative, (B) positive; EGFR IHC expression examples: (C) negative, (D) positive, EGFR gene status by
FISH examples: (E) diploid, (F) amplified.
Table 2 Molecular biomarkers analysis and correlations with PFS-6
N (%) PFS-6 P
EGFR by FISH (n¼19)
Genetic gain 9 (47.3%) 0 NS
Disomy 10 (52.7%) 30%
EGFR by IHC (n¼21)
Positive 8 (38.1%) 0 NS
Negative 13 (61.9%) 23%
p-Akt by IHC (n¼21)
Positive 10 (47.6%) 10% NS
Negative 11 (52.4%) 18%
EGFR¼Epidermal growth factor receptor; FISH¼fluorescence in situ hybridization;
IHC¼immunohistochemistry; NS, nonsignificant; p-Akt¼phosphorylated Akt;
PFS-6¼progression-free survival at 6 months.
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samplification. These correlations were stronger and statistically
significant among the 29 patients with GBM (P¼0.03 and 0.02,
respectively). Among six responders with sufficient tumour tissue,
none presented the EGFR truncated version known as EGFRvIII.
Low levels of p-Akt expression was also associated with TTP
(Po0.001).
Another study conducted retrospectively by Mellinghoff
et al (2005) on patients with GBM treated with two different
EGFR TKIs (gefinitib and erlotinib) showed results at least
partially in contrast with previous cited studies. In fact responses
to gefitinib were recorded for the first time and the importance of
EGFRvIII expression (especially in presence of PTEN expression)
on EGFR TKIs activity assessed in gliomas. However, in this study
unusual response evaluation criteria were used (patients were
considered responders if a o25% of tumour reduction was
achieved , clinical conditions and corticosteroid dosages were not
considered).
Despite a suggestion of a predictive role of PI3K pathway
inactivation by the latter two studies, no convincing molecular
predictor of EGFR TKIs efficacy have emerged.
Even in our analysis EGFR expression or amplification and
p-Akt expression, do not seem to provide useful information to
select HGG patients that could have a benefit from gefitinib.
The optimal biological dosage of gefitinib has yet to be defined.
Nor is it known whether gefitinib has a place in the treatment of
patients with HGG. However, further investigations should be
conducted to establish whether molecular determinants of clinical
effect can be used for patient selection in the treatment of GBM.
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